US court’s decision highlights risk of using a CMO prior to filing a patent application

While pharma and biotech companies are increasingly turning to CMO (contract manufacturing organization) partners earlier in the drug development process, they may want to reconsider engaging with a CMO prior to filing a patent after a recent ruling from the US Court of Appeals for the Federal Circuit.

Read more at http://www.outsourcing-pharma.com/Contract-Manufacturing/US-court-s-decision-highlights-risk-of-using-a-CMO-prior-to-filing-a-patent-application